<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03878030</url>
  </required_header>
  <id_info>
    <org_study_id>18-0149</org_study_id>
    <nct_id>NCT03878030</nct_id>
  </id_info>
  <brief_title>Effect of Nusinersen on Adults With Spinal Muscular Atrophy</brief_title>
  <official_title>Effect of Nusinersen on Motor Function in Adult Patients With Spinal Muscular Atrophy Types 2 and 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observational study of adult patients with spinal muscular atrophy types 2 and 3 receiving
      nusinersen
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observational study to assess effects of nusinersen on motor function in adult patients with
      spinal muscular atrophy who are both ambulatory and non-ambulatory. Subjects will receive
      standard of care with nusinersen intrathecal injection and undergo baseline and every 6 month
      motor assessments and pulmonary function testing during the first two years of treatment with
      nusinersen.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in quantitative motor function</measure>
    <time_frame>Two years</time_frame>
    <description>Primary Endpoint: Change from baseline to end of study in quantitative motor strength by dynamometry of upper limb muscles - shoulder abduction and elbow flexion/extension.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in upper limb motor function</measure>
    <time_frame>Two years</time_frame>
    <description>Change from baseline to end of study in upper limb module score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in 6 minute walk test in ambulatory patients</measure>
    <time_frame>Two years</time_frame>
    <description>Change in 6 minute walk test from baseline to end of study</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function by spirometry forced vital capacity (FVC)</measure>
    <time_frame>Two years</time_frame>
    <description>Change in FVC from baseline to end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in 10 meter walk test in ambulatory patients</measure>
    <time_frame>Two years</time_frame>
    <description>Change from baseline to end of study in the 10 meter walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in compound muscle action potential (CMAP) amplitude by nerve conduction velocity (NCV) criteria</measure>
    <time_frame>Two years</time_frame>
    <description>Change from baseline to end of study in CMAP amplitude of responses from median, ulnar and peroneal motor nerves</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in pulmonary function by spirometry forced expiratory volume (FEV)</measure>
    <time_frame>Two years</time_frame>
    <description>Change from baseline to end of study in FEV</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Adult Spinal Muscular Atrophy</condition>
  <arm_group>
    <arm_group_label>Subjects with spinal muscular atrophy types 2 and 3</arm_group_label>
    <description>Intrathecal nusinersen will be administered to all subjects per FDA approved label.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nusinersen</intervention_name>
    <description>Subjects will receive nusinersen and be observed with motor assessments for 24 months</description>
    <arm_group_label>Subjects with spinal muscular atrophy types 2 and 3</arm_group_label>
    <other_name>Spinraza</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The population to be studied are a homogenous group of adult subjects with 5q SMA seeking
        treatment with nusinersen. The subjects will have a broad phenotype spectrum of motor
        weakness including ability to ambulate, non-ambulatory and varying degrees of upper limb
        motor function and respiratory and swallow abilities, with some more affected and requiring
        invasive ventilation or NIV, and/or PEG tubes for nutrition.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Genetically confirmed 5q SMA

          -  ability to access intrathecal space for nusinersen injection

        Exclusion Criteria:

          -  Renal impairment

          -  thrombocytopenia

          -  inability to access intrathecal space by CT or flouro guided injection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony Geraci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwell Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwell Health Neuroscience</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.</citation>
    <PMID>29091570</PMID>
  </results_reference>
  <results_reference>
    <citation>Mercuri E, Darras BT, Chiriboga CA, Day JW, Campbell C, Connolly AM, Iannaccone ST, Kirschner J, Kuntz NL, Saito K, Shieh PB, Tulinius M, Mazzone ES, Montes J, Bishop KM, Yang Q, Foster R, Gheuens S, Bennett CF, Farwell W, Schneider E, De Vivo DC, Finkel RS; CHERISH Study Group. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504.</citation>
    <PMID>29443664</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 10, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwell Health</investigator_affiliation>
    <investigator_full_name>Anthony Geraci</investigator_full_name>
    <investigator_title>Director, Neuromuscular medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

